Proteome Sciences. AGM Statement.

OFF TOPIC - While you're discussing Reneuron, take a look at what's happening with Tepnel(TED)re their announcement today (see below) - a far cry from the days of trying to sell their DNA analysis machines! Still 8.5p to buy and with a market cap of £17m.


Tepnel Life Sciences Agreement with Tepnel


RNS Number:3876O
ABCAM Plc
21 December 2006


For immediate release 21 December 2006

ABCAM PLC

("Abcam" or "the Company")


International Distribution Agreement Signed with Tepnel Life Sciences



Abcam plc (AIM: ABC), the rapidly growing company that markets antibodies via an online catalogue, is pleased to announce that it has signed a global licensing agreement with Tepnel Life Sciences PLC ("Tepnel") (AIM: TED), the UK-based international molecular diagnostics and research products & services group, for the distribution of Tepnel's Diaclone range of diagnostic and research products.

The Diaclone range includes more than 350 immunological products designed for
therapy, diagnostic and research applications. The distribution partnership
with Tepnel is an exclusive agreement for sales in Japan, Canada, and South
America. In the USA Abcam will share the sales rights for the Diaclone range
with Tepnel. The sales arrangement is non-exclusive elsewhere in the world.

As part of the agreement Abcam will give Tepnel an upfront payment and has
guaranteed to a minimum level of annual sales.

Commenting on the announcement, Jonathan Milner, Abcam's Chief Executive
Officer, said: "We are excited about this agreement with Tepnel where we have
worldwide sales rights to a wide range of products. This opportunity allows
Abcam to expand its product range into antibody related products and gives us an opportunity to sell more products across a wide geographical footprint."

Dr Allan Brown, Managing Director of Tepnel Research Products & Services,
commented: "The agreement with Abcam is a significant one for Tepnel as our
Diaclone product range is already one of the world's leading sources of
immunological products and with our new partnership, we will be able to further
extend our market share. As the number one player in this market, Abcam
possesses the awareness, reputation and know-how to help attain the market
potential for Diaclone products."